FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Erythropoietin topics
Erythropoietin
Red Blood Cell
Recombinant
Nucleic Acid
Genetically
Regulatory Sequence
Endogenous
Peptide Sequence
Carbamylated
Ischemic Stroke
Therapeutical
Intracranial
Thrombopoietin
Leukemia Inhibitory Factor
Somatostatin

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Erythropoietin patents



      
           
This page is updated frequently with new Erythropoietin-related patent applications. Subscribe to the Erythropoietin RSS feed to automatically get the update: related Erythropoietin RSS feeds. RSS updates for this page: Erythropoietin RSS RSS


Date/App# patent app List of recent Erythropoietin-related patents
04/30/15
20150119325
 Methods for the production of cytoprotective asialo-erythropoietin in plants and its purification from plant tissues patent thumbnailMethods for the production of cytoprotective asialo-erythropoietin in plants and its purification from plant tissues
The present invention provides methods for the high-level production of recombinant human erythropoietin (rhuepo) derivative, asialoerythropoietin (asialo-rhuepo), in plants. The methods for producing asialo-rhuepo comprise making a plant or at least one plant cell that comprises a promoter that drives expression in a plant cell operably linked to a polynucleotide encoding a human erythropoieting fusion protein and a promoter that drives expression in a plant cell operably linked to a polynucleotide encoding n-glycosylation modification enzyme, particularly a mammalian β1,4-galactosyltransferase.
North Carolina Central University
04/30/15
20150118187
 Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof patent thumbnailMicro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof
The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a nucleic acid sequence operably linked to one or more regulatory sequences. The present invention is further directed to methods providing sustained expression of therapeutic polypeptides and prolonged therapeutic effects, such as erythropoietin and interferon..
Medgenics Medical Israel Ltd.
04/23/15
20150110743
 Long lasting drug formulations patent thumbnailLong lasting drug formulations
The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.. .
Medgenics Medical Israel Ltd.
03/26/15
20150087695
 Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo patent thumbnailTreatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
Oligonucleotide compounds modulate expression and/or function of erythropoietin (epo) polynucleotides and encoded products thereof. Methods for treating diseases associated with erythropoietin (epo) comprise administering one or more oligonucleotide compounds designed to inhibit the epo natural antisense transcript to patients..
Curna, Inc.
03/26/15
20150087065
 Method for generation of conditionally immortalized hematopoietic progenitor cell lines with multiple lineage potential patent thumbnailMethod for generation of conditionally immortalized hematopoietic progenitor cell lines with multiple lineage potential
The present invention is a method and kits for generating a homogenous population of hematopoietic progenitor cells capable of differentiating into a hematopoietic cell lineage. Whereas the combination of homeobox-b8 protein and fms-like tyrosine kinase 3 ligand generate cells with the potential to differentiate into different myeloid and lymphoid cell types, homeobox-a7 protein and erythropoietin generate cells with the potential to differentiate into erythropoietic or thrombopoietic cell types..
St. Jude Children's Research Hospital
03/26/15
20150087060
 Method for inducing erythropoietin-producing cell patent thumbnailMethod for inducing erythropoietin-producing cell
An object of the present invention is to provide a method for inducing the differentiation of erythropoietin-producing cells from human pluripotent stem cells. The above object is achieved by providing a method for inducing the differentiation of erythropoietin-producing cells from human pluripotent stem cells using a medium containing a specific growth factor and a specific compound..
Kyoto University
02/05/15
20150038403
 Compounds that bind to the erythropoietin receptor patent thumbnailCompounds that bind to the erythropoietin receptor
The present invention provides mimetics of erythropoietin that bind to the erythropoietin receptor and that are suitable for use in pharmaceutical compositions. The present invention also provides methods of treatment using the mimetics of erythropoietin as well as methods of making the mimetics of erythropoietin..
01/29/15
20150031696
 Cyanoisoquinoline compounds and methods of use thereof patent thumbnailCyanoisoquinoline compounds and methods of use thereof
The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:.
Fibrogen, Inc.
01/15/15
20150018274
 Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators patent thumbnailErythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
The present invention provides isolated stabilized epo-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized epo-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof.. .
University Of Medicine And Dentistry Of New Jersey
01/08/15
20150011574
 (2-heteroarylamino) succinic acid derivatives patent thumbnail(2-heteroarylamino) succinic acid derivatives
The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by the formula (1) wherein r1: an aromatic hydrocarbon ring group or an aromatic heterocyclic group; r2: a hydrogen atom, an alkyl group, or a heterocycloalkyl group; r3: a hydrogen atom or an alkyl group; a: a hydrogen atom or a hydroxy group; l: —nhco— or —och2—; and x: a nitrogen atom or ═ch—..
Daiichi Sankyo Company, Limited
01/08/15
20150011552

4-alkanoylamino-3-pyrazolone derivative


The present invention provides a compound which enhances the production of erythropoietin. The present invention provides, for example, a compound represented by the formula (1) wherein r1: -q1, -q1-x-q2, or -q1-x-q2-y-q3: a monocyclic or bicyclic aromatic heterocyclic group; q2, q3: an aromatic hydrocarbon ring group or a monocyclic aromatic heterocyclic group; x: —conh—, —conhch2—, —ch2och2—, —nhch2ch2—, or the like; y: a single bond, —o—, —(ch2)n—, or —o—(ch2)n—; m, n: an integer from 1 to 3; r2: h or an alkyl group; and r3: h, an alkoxycarbonyl group, a carboxy group, an aromatic hydrocarbon ring group, or a monocyclic aromatic heterocyclic group..
Daiichi Sankyo Company, Limited
12/25/14
20140378378

Erythropoietin-derived peptide and use therefor


Provided are a peptide, which has an amino acid sequence of seq id no. 1 and is effective for the prevention of cell damage, and a pharmaceutical composition for preventing cell damage, the pharmaceutical composition including the peptide as an active component.
11/20/14
20140343094

Novel nitrogen-containing heteroaryl compounds and methods of use thereof


The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.. .
10/30/14
20140323401

Tissue protective peptides and uses thereof


The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex.
10/23/14
20140315802

Derivatisation of erythropoietin (epo)


The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..
10/16/14
20140309407

Derivatisation of erythropoietin (epo)


The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..
10/16/14
20140309166

Derivatisation of erythropoietin (epo)


The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..
10/02/14
20140296318

Novel tissue protective erythropoietin receptor (nepor) and methods of use


Methods of determining whether a patient is suitable for erythropoietin (epo) therapy, including (a) isolating a tissue sample from said patient; (b) determining the level of expression of eph-b4 in said sample; and (c) correlating a presence of eph-b4 expression to a negative physiological response to epo therapy). In addition, methods of enhancing the effectiveness of epo therapy in a patient by administering to said patient, in conjunction with epo therapy, an sirna specific for eph-b4..
10/02/14
20140296175

Composition and inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell


A composition for inducing erythropoietin (epo)-mediated haemoglobin (hb) expression in a nonhaematopoietic cell of a subject is provided. The composition includes a compound represented by formula (i), wherein r is a glycosyl group; and a pharmaceutical acceptable carrier..
09/25/14
20140288172

Erythropoietin production-promoting agent


A therapeutic and/or prophylactic agent for renal anemia comprising alas and an erythropoietin production promoter comprising alas.. .
09/11/14
20140255337

Methods of treating cognitive impairment


The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (flt3) ligand, interleukin-6 (il-6), macrophage migration inhibitory factor (mif), interleukin-1 (il-1), interleukin-3 (il-3), erythropoietin (epo), vascular endothelial growth factor a (vegf-a), hypoxia-inducible transcription factor (hif-1alpha), insulin like growth factor-1 (igf-1), tumor necrosis factor (tnf), granulocyte colony-stimulating factor (g-csf), granulocyte/macrophage colony-stimulating factor (gm-csf), macrophage colony-stimulating factor (m-csf), stem cell factor (scf), darbepoetin (aranesp), and metalloproteinases, to an animal or person in need of treatment..
08/28/14
20140243510

Methods for purifying erythropoietin analogs having lower isoelectric point


The present invention relates to a method for purifying an erythropoietin analog having a low isoelectric point below 4 by adding an n-linked sugar chain with high purity. In accordance with the present invention, the erythropoietin analog having an isoelectric point below 4, which is an isoform having more sialic acid residues, can be effectively purified via three-step chromatographic processes in short time at lower cost..
08/28/14
20140243324

Use of hematopoietic growth factor mimetics


The present invention relates to uses of small molecule mimetics of hematopoietic growth factors. In particular the present invention relates to uses of small molecule mimetics of erythropoietin..
08/07/14
20140216950

Erythropoietin receptor modified electrode and its preparation method and application


The invention discloses an erythropoietin receptor modified electrode, which is a glassy carbon electrode with erythropoietin receptor as recognition element fixed onto the electrode surface via zno sol-gel. The modified electrode can be prepared easily, and its performance is stable.
07/17/14
20140200180

Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens


Methods for producing proteins and glycoproteins in pichia pastoris that lack detectable cross binding activity to antibodies made against host cell antigens are described. In particular, methods are described wherein recombinant pichia pastoris strains that do not display a β-mannosyltransferase 2 activity with respect to an n-glycan or o-glycan and do not display at least one activity selected from a β-mannosyltransferase 1, 3, and 4 activity to produce recombinant proteins and glycoproteins.
06/26/14
20140178335

Use of il-12 to generate endogenous erythropoietin


The present invention relates to the use of exogenous interleukin-12 (il-12) for increasing endogenous production of erythropoietin.. .
06/12/14
20140163207

Method for purifying pegylated erythropoietin


Herein is reported a method for the purification of a protein comprising erythropoietin and a single poly (ethylene glycol) residue from reaction by-products or not reacted starting material by a cation exchange chromatography method. It has been found that by employing a cation exchange sp sephacryl™ s 500 hr chromatography material conditioned to a conductivity of 21 ms/cm and a linear gradient elution a fusion protein of erythropoietin and a single poly (ethylene glycol) residue can be obtained in a single step with high purity and yield..
06/12/14
20140161766

Tetrameric cytokines with improved biological activity


The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-mab dnl complex comprises an igg antibody attached to two ad (anchor domain) moieties and four cytokines, each attached to a ddd (docking and dimerization domain) moiety.
06/05/14
20140154205

Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications


A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of erythropoietin and about 100-300 mg per cm2 wound tissue of fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject.
05/22/14
20140142122

Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival


Disclosed herein are erythropoietin-mimetic compounds of formula i, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor.
05/08/14
20140128472

Treatment and prevention of diseases related to oxidative stress


The present invention relates to the field of treatment and prevention of conditions related to oxidative stress and hormone resistance. Preferably, insulin resistance, erythropoietin resistance and acetyl-choline resistance are in the focus.
05/01/14
20140120100

Compositions and methods for preventing erythropoietin-associated hypertension


The inventors have discovered that both soluble erythropoietin-binding protein and antibodies against the erythropoietin-binding protein, when they are administered to a mammal along with erythropoietin (epo), prevent or reduce the blood pressure increase normally caused by erythropoietin, while not affecting the hematocrit increase that is the purpose of epo treatment. The invention provides a method of treating anemia in a mammal involving: administering erythropoietin (epo) to the mammal; and administering to the mammal an agent selected from a soluble epo-binding protein (epo-bp), a recognition protein that binds epo receptor on an extracellular soluble portion of the epo receptor, and a combination thereof.
02/20/14
20140053288

Epo knockout gfp anemic mouse


The present invention relates to a model animal spontaneously developing anemia. More specifically, the invention relates to a transgenic non-human mammal spontaneously developing anemia associated with a postnatal decrease in production of erythropoietin (epo), epo-producing cells prepared from the transgenic non-human mammal, and a screening method using the epo-producing cells..


Popular terms: [SEARCH]

Erythropoietin topics: Erythropoietin, Red Blood Cell, Recombinant, Nucleic Acid, Genetically, Regulatory Sequence, Endogenous, Peptide Sequence, Carbamylated, Ischemic Stroke, Therapeutical, Intracranial, Thrombopoietin, Leukemia Inhibitory Factor, Somatostatin

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Erythropoietin for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Erythropoietin with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         













0.2307

3575

0 - 1 - 71